Coya Therapeutics (COYA) EBIT (2022 - 2026)
Coya Therapeutics (COYA) reported EBIT of -$7.6 million for Q1 2026, little changed on a YoY basis from -$7.6 million in Q1 2025, and down 26.68% sequentially from -$6.0 million in Q4 2025.
Coya Therapeutics (COYA) EBIT (2022 - 2026) Analysis & Trends
Coya Therapeutics (COYA) has 5 years of EBIT data on file, last reported at -$7.6 million in Q1 2026.
- For the quarter ending Q1 2026, EBIT changed 0.48% year-over-year to -$7.6 million; the trailing twelve-month figure through Mar 2026 stood at -$22.5 million (down 15.81% YoY), and the FY2025 full-year result was -$22.6 million, down 30.76% from the prior year.
- EBIT fell to -$7.6 million in Q1 2026, from -$6.0 million in the prior quarter.
- In the past five years, EBIT ranged from a high of $1.8 million in Q4 2023 to a low of -$7.7 million in Q1 2025.
- A 5-year average of -$3.8 million and a median of -$3.4 million in 2022 frame the typical range for EBIT.
- Across the five-year window, EBIT surged 190.6% in 2023 and tumbled 324.79% in 2024, its largest moves.
- Tracing COYA's EBIT over 5 years: stood at -$2.0 million in 2022, then surged by 190.6% to $1.8 million in 2023, then slumped by 324.79% to -$4.1 million in 2024, then plunged by 47.81% to -$6.0 million in 2025, then slipped by 26.68% to -$7.6 million in 2026.
- Business Quant data shows COYA's EBIT at -$7.6 million in Q1 2026, -$6.0 million in Q4 2025, and -$2.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 468.11 Bn | 463.32 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 122.48 Bn | 115.23 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 70.30 Bn | 61.55 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.77 Bn | 62.77 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 55.66 Bn | 50.47 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.42 Bn | 34.41 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Coya Therapeutics | 96.92 Mn | 46.19 Mn | - | -7.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.64 Mn |
| Dec 31, 2025 | -6.03 Mn |
| Sep 30, 2025 | -2.43 Mn |
| Jun 30, 2025 | -6.41 Mn |
| Mar 31, 2025 | -7.68 Mn |
| Dec 31, 2024 | -4.08 Mn |
| Sep 30, 2024 | -4.45 Mn |
| Jun 30, 2024 | -3.24 Mn |
| Mar 31, 2024 | -5.48 Mn |
| Dec 31, 2023 | 1.82 Mn |
| Sep 30, 2023 | -3.56 Mn |
| Jun 30, 2023 | -3.25 Mn |
| Mar 31, 2023 | -2.90 Mn |
| Dec 31, 2022 | -2.00 Mn |
| Sep 30, 2022 | -2.66 Mn |
| Jun 30, 2022 | -3.45 Mn |
| Mar 31, 2022 | -1.70 Mn |